Limitation On Future Patent Protection For Biosimilars?
August 9, 2012, 1:36 PM EDT
Law360, New York (August 9, 2012, 1:36 PM EDT) -- On Aug. 3, 2012, the U.S. Court of Appeals for the Federal Circuit issued an opinion vacating a preliminary injunction that had been granted by the U.S. District Court for the District of Massachusetts to Momenta Pharmaceuticals Inc. and Sandoz Inc. (collectively, "Momenta"). See Momenta Pharmaceuticals Inc., et al. v. Amphastar Pharmaceuticals Inc., et al., Nos. 2012-1062, ‑1103, -1104 (Fed. Cir. Aug. 3, 2012).
Momenta — the sole marketer in the United States of a generic version of Sanofi-Aventis U.S. LLC's branded drug Lovenox (enoxaparin) until...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.